AN2 Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ANTX Nasdaq 2836 www.an2therapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for AN2 Therapeutics, Inc.

AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum - May 7th, 2026 2:01 pm
AN2 Therapeutics Announces Initiation of Phase 2 Investigator-Initiated Clinical Trial of Epetraborole for Mycobacterium abscessus Complex Lung Disease - Mar 31st, 2026 5:00 am
AN2 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business and Scientific Highlights - Mar 17th, 2026 2:00 pm
AN2 Therapeutics Announces $40 Million Private Placement Financing - Mar 9th, 2026 5:00 am
AN2 Therapeutics Announces Plans to Advance Oral Epetraborole into Phase 2 Study for Polycythemia Vera (PV) - Mar 3rd, 2026 2:00 pm
AN2 Therapeutics to Participate in Fireside Chat at Leerink Global Healthcare Conference - Feb 17th, 2026 5:00 am
AN2 Therapeutics Announces FDA Clearance to Proceed with 90-Patient Investigator-Initiated Trial (IIT) of Epetraborole in Patients with M. abscessus Lung Disease - Jan 12th, 2026 5:00 am
AN2 Therapeutics (ANTX) Upgraded to Buy: What Does It Mean for the Stock? - Jan 9th, 2026 10:00 am
Are Medical Stocks Lagging Allogene Therapeutics (ALLO) This Year? - Jan 9th, 2026 7:40 am
AN2 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business and Scientific Highlights - Nov 12th, 2025 2:01 pm
AN2 Therapeutics Announces Research Collaboration With GSK to Advance Boron-Based LeuRS-Inhibitors Targeting Tuberculosis (TB) - Nov 10th, 2025 5:00 am
AN2 Therapeutics to Participate in Fireside Chat at Evercore HealthCONx Conference - Nov 6th, 2025 3:03 pm
AN2 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business and Scientific Highlights - Aug 12th, 2025 2:01 pm
AN2 Therapeutics Commences First-in-Human Clinical Trial of Oral AN2-502998 for Chagas Disease - Aug 12th, 2025 5:00 am
AN2 Therapeutics and DNDi Collaborate on Clinical Development of Promising New Oral Compound to Treat Chronic Chagas Disease - Jul 23rd, 2025 5:00 am
AN2 Therapeutics Reports Key Insights from 200-Patient Observational Study in Acute Melioidosis, Laying Groundwork for Phase 2 Proof-of-Concept Trial of Epetraborole - Jun 30th, 2025 5:00 am
Positive Signs As Multiple Insiders Buy AN2 Therapeutics Stock - Jun 28th, 2025 7:39 am
AN2 Therapeutics Announces Poster Presentation Highlighting M. Abscessus Data at 2025 Colorado Mycobacteria Conference - May 29th, 2025 5:00 am
AN2 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business and Scientific Highlights - May 13th, 2025 2:01 pm